Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 8/20 | 0.69 |
| ▸ | CTSL | P07711 | 4/20 | 0.69 |
| ▸ | CTSB | P07858 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA5A | P35218 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 8/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.49 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.49 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.49 |
| ▸ | CTSD | P07339 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6361534 | 0.91 | CTSS (0.57) | CTSSCTSLCTSBCA2CA5A | |
| SCHEMBL6364364 | 0.83 | CTSK (0.76) | CTSSCTSLCTSBCA5ACTSK | |
| SCHEMBL6361583 | 0.83 | CTSK (0.76) | CTSSCTSLCTSBCA5ACTSK | |
| SCHEMBL9826204 | 0.82 | CTSS (0.71) | CTSSCTSLCTSBCA2CA5A | |
| SCHEMBL25693730 | 0.81 | CTSS (0.73) | CTSSCTSLCTSBCTSKMEN1 | |
| SCHEMBL10415577 | 0.81 | CTSS (0.73) | CTSSCTSLCTSBCTSKMEN1 | |
| SCHEMBL6358711 | 0.81 | CTSL (0.65) | CTSSCTSLCTSBCA2CA5A | |
| SCHEMBL2446560 | 0.81 | CTSL (0.80) | CTSSCTSLCTSBCA2CA5A | |
| SCHEMBL19134416 | 0.80 | CTSS (0.71) | CTSSCTSLCTSBCA2CA5A | |
| SCHEMBL5708380 | 0.80 | CTSS (0.71) | CTSSCTSLCTSBCA2CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6858591-B2 | Antibiotic AA 896 analogs | WYETH HOLDINGS CORPORATION (US) | 2005-02-22 | — | — | US | disclosed |
| US-20030087874-A1 | 2-amino-3-hydroxy-3-uridyl-propanoic acid ester derivatives | AMERICAN CYANAMID COMPANY | 2003-05-08 | — | — | US | disclosed |
| WO-2002086139-A1 | ANTIBIOTIC AA 896 ANALOGS | WYETH HOLDINGS CORPORATION (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087874-A1 | 2-amino-3-hydroxy-3-uridyl-propanoic acid ester derivatives | UMPS, METTL3, FPR3 | CTSS 3983/4885CTSL 2129/4885CTSB 4098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.